Moshe Spinowitz advises multinational companies in connection with cross-border mergers and acquisitions, and post-acquisition restructuring and integration transactions. He also represents clients on a range of tax controversy matters during all phases of IRS audits and appeals.


Mr. Spinowitz has advised several multinational companies on the integration and restructur­ing of their operations following large cross-border acquisitions. He also has counseled phar­maceutical and technology companies in connection with the structuring of their intellectual property holdings, as well as a variety of companies in connection with U.S. tax reform. Mr. Spinowitz also has successfully represented several multinational corporations before IRS appeals involving intercompany financing transactions and other cross-border tax matters.

Select representations include:

  • Bottomline Technologies in its pending $2.6 billion acquisition by Thomas Bravo;
  • Dicerna Pharmaceuticals in its $3.3 billion acquisition by Novo Nordisk;
  • Waldencast Acquisition Corp. in its pending business combination with Obagi Cosmeceuticals and Milk Makeup;
  • L’Occitane International in its acquisition of Sol de Janeiro Holdings;
  • AspenTech in its pending $11 billion combination with the industrial software business of Emerson Electric;
  • ArQule, Inc. in its $2.7 billion acquisition by a subsidiary of Merck & Co., Inc.;
  • Juno Therapeutics in its $9 billion acquisition by Celgene;
  • Clementia Pharmaceuticals Inc. in its $1.3 billion acquisition by Ipsen S.A.;
  • Gilead Sciences, Inc. in its $11.9 billion acquisition of Kite Pharma, its acquisition of Cell Design Labs for up to $567 million, and its research and development collaboration with, and equity investment in, Galapagos NV;
  • Biogen Inc. in the spin-off of its hemophilia business as an independent public company called Bioverativ;
  • Konecranes plc in its acquisition of Terex Corporation’s material handling and port solutions unit for $1.28 billion;
  • Merrimack Pharmaceuticals, Inc. in its sale of cancer treatment drugs Onivyde and generic Doxil to Ipsen S.A. for up to $1.025 billion; and
  • Spectra Energy Corp in its combination with Enbridge Inc. for $28 billion.

In recognition of his work, Mr. Spinowitz has been honored as one of Massachusetts Lawyers Weekly’s Go To Lawyers for Taxation and repeatedly selected for inclusion in Chambers USA. He also was named as a recipient of Bloomberg’s Tax Portfolio Author of the Year Award for his work on the Bloomberg Tax portfolio “Outbound Tax Planning for U.S. Multinational Corporations (Portfolio 6380).” Prior to joining Skadden, he served as a law clerk to Judge Michael Boudin on the U.S. Court of Appeals for the First Circuit, and Justice Antonin Scalia on the U.S. Supreme Court.



  • J.D., Harvard Law School, 2006 (magna cum laude; Articles Editor, Harvard Law Review)
  • B.A., Harvard College, 2002 (summa cum laude)


  • Massachusetts
  • District of Columbia


  • Law Clerk to Judge Michael Boudin, U.S. Court of Appeals for the First Circuit
  • Law Clerk to Associate Justice Antonin Scalia, U.S. Supreme Court

Moshe Spinowitz